A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Apitolisib (Primary) ; Bevacizumab; Paclitaxel
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors Genentech
- 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 04 Jan 2013 Planned End Date changed from 1 Jan 2014 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 04 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.